BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Heart
,
Laryngoscope
,
Bleomycin
,
rs7903146
,
FOXP1
,
G-protein-coupled receptor binding
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CD52
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
B lymphocyte (naive) of spleen
Whole blood
B lymphocyte (IgM memory) of spleen
T Lymphocyte (CD4+) of peripheral blood
Monocyte of peripheral blood
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Bacterial sepsis of newborn
Transplanted organ rejection
Disease caused by parasite
Sepsis due to coagulase negative Staphylococcus
Renal interstitial fibrosis
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
alemtuzumab
phorbolol-12-myristate-13-acetate
9-(2-hydroxy-3-nonyl)adenine
16-ketoestradiol
1,10-phenanthroline
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Bcr
Abl1
SLAMF7
PEX5
ILK
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sc…
Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosi…
Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disea…
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disor…
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows …
Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and T…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ